India struck down a patent covering GlaxoSmithKline's breast-cancer drug Tykerb over concerns that the treatment is not innovative enough to deserve its own patent. A GSK representative said the company was evaluating an appeal. Similarly, a Roche representative confirmed that India had canceled divisional patents for the company's breast cancer treatment Herceptin over improper patent submissions.
India lifts patents for GSK, Roche's breast cancer drugs
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||